P286 Variation of outcomes in inflammatory bowel disease at ten Australasian centres - Crohn's Colitis Cure (CCC) Data Insights Program
Judith McNamara(Liverpool Hospital), Susan J. Connor(Liverpool Hospital), Kate D. Lynch(Royal Adelaide Hospital), Ian C. Lawrance(The University of Western Australia), Joseph L. Pipicella(Ingham Institute), Watson Ng(Liverpool Hospital), G Walker(The University of Queensland), Richard B. Gearry(Waitaki Biosciences (New Zealand)), Jane M. Andrews(Health Net), Simon Ghaly(UNSW Sydney), Jakob Begun(Translational Research Institute), Michael Schultz, Wayne H. Wilson(Lyell McEwin Hospital), Graham Radford‐Smith(QIMR Berghofer Medical Research Institute)
Cited by 2
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k